Drug news
NICE now recommends combination Farydak + Velcade (panobinostat + bortezomib+ dexamethasone) to treat multiple myeloma- Novartis
The National Institute for Health and Care Excellence (NICE) in a final appraisal now recommends Farydak + Velcade (panobinostat + bortezomib+ dexamethasone) from Novartis (subject to a discount) as third line treatment for patients with relapsed/refractory multiple myeloma who have received at least two prior therapies .
Comment:Patients receiving Farydak combination had a delay in their disease progression of about 7.8 months more than those given Velcade +dexamethasone alone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.